ImpeDx Diagnostics has secured exclusive rights to develop and market a novel system for rapid antimicrobial susceptibility testing (AST), a multibillion dollar market.

Our mission is to reduce healthcare costs and the growing rate of antibiotic resistance while saving lives. By addressing the time consuming element (AST) of the two-step process: identification (ID) & susceptibility testing (AST). Healthcare providers use the two-step process to treat patients suffering from infections with targeted antibiotics and doses. ImpeDx is responding to an ever-growing need and significant medical problem, infections are the leading cause of death in hospitals today and antibiotic resistance is increasing at staggering rates. Our technology compresses the typical AST processes from days to under 5 hours. In some cases, for slow growing bacteria, AST requires weeks; in these instances, we achieve results in under 5 days. Not only will our rapid testing platform improve patient outcomes, but it will also have a major impact on healthcare savings.